

**AMENDMENT TO THE CLAIMS:**


This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1-31. (canceled)

32. (currently amended) A method for treating or managing a metalloproteinase (MMP)-related disease or disorder selected from cancer and TNF-alpha-mediated inflammation in a mammal comprising administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of a compound of the Formula (I):

(I)



wherein

R is saturated or unsaturated alkyl, cycloalkyl, arylalkyl or cycloalkyl-alkyl radical having from 1 to 28 carbon atoms which may be interrupted by any combination of 1-6 oxygen and/or nitrogen atoms, provided that no two oxygen atoms or an oxygen and a nitrogen atom are directly connected to each other; and

M denotes a hydrogen or a physiologically acceptable cation.

33. (previously presented) The method according to claim 32, wherein said method further comprises treating the mammal with additional therapeutic treatment.

34. (previously presented) The method according to claim 32, wherein said mammal is a human.

35. (previously presented) The method according to claim 32, wherein said MMP-related disease or disorder is selected from the group consisting of cancer, trauma, inflammatory conditions and diseases, atherosclerosis, thrombotic disorders, arthritis, hemorrhage, rheumatic diseases, autoimmune diseases, and migraine.

36. (previously presented) The method according to claim 32, wherein said MMP-related disease or disorder is an inflammatory condition or disease selected from the group consisting of arthritides, rheumatoid arthritis, osteoarthritis, restenosis, psoriasis, systemic lupus erythematosus, inflammatory bowel syndrome, Crohn's disease, migraine, gingivitis, periodontitis, meningitis, tropical spastic paraparesis, sepsis, bullous skin disorders, acne and inflammation due to infectious diseases.

37. (previously presented) The method according to claim 32, wherein said MMP-related disease or disorder is selected from the group consisting of oxidative damage, osteoporosis, diabetes, hemorrhage, ocular pathologies and retinopathies, diabetic retinopathy, glaucoma, macular degeneration, cataract, retinal detachment and retinal tears, multiple sclerosis (MS), motor neuron disease (MND), amyotrophic lateral sclerosis (ALS), Guillain-Barré, Huntington disease, Pick's disease, dementia syndrome, vascular dementia, multiple infarct dementia, HIV-induced neural disorders, and neuronal tissue trauma.

38. (previously presented) The method according to claim 32, wherein R in the compound of Formula 1 is a phenylakyl, and alky interrupted by zero to three oxygen atoms, or a monoalkyl ether of mono-, di-, or tri-ethylene glycol.

39. (previously presented) The method according to claim 32, wherein R in the compound of Formula 1 is selected from the group consisting of:  $C_8H_{17}$ ,  $C_8H_{17}OCH_2CH_2$ ,  $C_{18}H_{37}$ ,  $C_{18}H_{37}OCH_2CH_2$ , benzyl- $CH_2OCH_2CH_2$ ,  $C_{12}H_{25}OCH_2CH_2$ ,  $C_{12}H_{25}(OCH_2CH_2)_2$  and  $C_{12}H_{25}(OCH_2CH_2)_3$ .

40. (previously presented) The method according to claim 32 wherein metalloproteinase is MMP-9.

41. (previously presented) The method according to claim 35, wherein said MMP-related disease or disorder is cancer.

42. (previously presented) The method of claim 41, wherein said cancer includes cancer metastasis.

43. (previously presented) The method according to claim 32, wherein said MMP-related disease or disorder is an angiogenesis-dependent disease.

44. (previously presented) The method according to claim 43 wherein said angiogenesis-dependent disease is selected from cancerous tumors, arthritis, psoriasis, macular degeneration, chronic inflammation, and diabetic retinopathy.

45. (previously presented) The method according to claim 33, wherein said additional treatment is selected from the group consisting of chemotherapy, irradiation therapy, immunotherapy, genetic therapy and surgery.

46. (previously presented) The method according to claim 32, wherein said compound of Formula 1 is selected from the group consisting of:

1,2-bis(2-aminophenoxy)ethane, N,N' -di(2-octoxyethyl acetate),N, N' -diacetic acid;

1,2-bis(2-aminophenoxy)ethane, N, N' -di(2-octodecyloxyethyl acetate),N, N' -diacetic acid;

1,2-bis(2-aminophenoxy)ethane, N, N' -di(2-benzyloxyethyl acetate),N, N' -acetic acid;

1,2-bis(2-aminophenoxy)ethane, N, N' -di(2-dodecyloctoxyethyl acetate),N, N' -diacetic acid;

1,2-bis(2-aminophenoxy)ethane, N, N' -di[2-(2-dodecyloxyethoxy)-ethyl acetate],N, N' -diacetic acid; and

1,2-bis(2-aminophenoxy)ethane, N, N' -di{2[2-(2-dodecyloxyethoxy)ethoxy]-ethyl acetate},N, N' -diacetic acid.